See more : Bridgewater Bancshares, Inc. (BWBBP) Income Statement Analysis – Financial Results
Complete financial analysis of Basilea Pharmaceutica AG (BPMUF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Basilea Pharmaceutica AG, a leading company in the Biotechnology industry within the Healthcare sector.
- PC Partner Group Limited (1263.HK) Income Statement Analysis – Financial Results
- Eminent Gold Corp. (EMGDF) Income Statement Analysis – Financial Results
- Fuller, Smith & Turner P.L.C. (FSTA.L) Income Statement Analysis – Financial Results
- MagIndustries Corp. (MAAFF) Income Statement Analysis – Financial Results
- Quotient Limited (QTNT) Income Statement Analysis – Financial Results
Basilea Pharmaceutica AG (BPMUF)
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.63M | 147.77M | 148.12M | 127.63M | 134.38M | 132.56M | 101.52M | 65.98M | 51.65M | 42.50M | 40.95M | 57.88M |
| Cost of Revenue | 26.79M | 24.60M | 24.07M | 24.05M | 18.87M | 20.30M | 9.03M | 5.35M | 60.08M | 54.38M | 53.35M | 63.26M |
| Gross Profit | 130.84M | 123.16M | 124.05M | 103.58M | 115.51M | 112.26M | 92.50M | 60.64M | -8.42M | -11.88M | -12.40M | -5.38M |
| Gross Profit Ratio | 83.00% | 83.35% | 83.75% | 81.15% | 85.96% | 84.69% | 91.11% | 91.90% | -16.30% | -27.95% | -30.28% | -9.30% |
| Research & Development | 77.85M | 73.80M | 93.16M | 97.41M | 102.66M | 104.94M | 53.49M | 48.45M | 60.08M | 70.08M | 53.35M | 58.86M |
| General & Administrative | 33.78M | 30.82M | 29.72M | 29.42M | 0.00 | 0.00 | 0.00 | 55.88M | 51.41M | 29.99M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 30.82M | 29.72M | 29.42M | 30.05M | 0.00 | 0.00 | 200.00K | 300.00K | 100.00K | 0.00 | 0.00 |
| SG&A | 33.78M | 30.82M | 29.72M | 29.42M | 30.05M | 31.41M | 53.14M | 56.08M | 51.71M | 30.09M | 21.31M | 42.22M |
| Other Expenses | 0.00 | 852.00K | -1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 111.64M | 102.35M | 121.04M | 124.99M | 131.18M | 136.35M | 106.63M | 104.53M | 111.78M | 30.01M | 20.89M | 46.66M |
| Cost & Expenses | 138.43M | 126.95M | 145.11M | 149.04M | 150.05M | 156.65M | 115.66M | 109.87M | 114.31M | 84.38M | 74.24M | 16.60M |
| Interest Income | 1.69M | 326.00K | 66.00K | 104.00K | 28.00K | 6.53M | 6.65M | 6.38M | 6.00K | 364.00K | 293.60K | 0.00 |
| Interest Expense | 11.20M | 9.85M | 8.15M | 7.59M | 6.42M | 6.55M | 6.68M | 6.41M | 154.00K | 54.00K | 0.00 | 291.26K |
| Depreciation & Amortization | 1.58M | 3.10M | 2.45M | 2.29M | 1.64M | 1.85M | 1.99M | 2.32M | 2.53M | 2.29M | 2.72M | 3.64M |
| EBITDA | 23.24M | 23.05M | 2.11M | -5.89M | -14.32M | -22.24M | -10.36M | -41.57M | -59.16M | -39.54M | -30.57M | -47.21M |
| EBITDA Ratio | 14.74% | 15.62% | 1.75% | -16.15% | -10.66% | -16.78% | -11.96% | -63.00% | -116.41% | -93.04% | -74.65% | -75.17% |
| Operating Income | 19.21M | 18.54M | 1.19M | -8.22M | -17.20M | -24.10M | -14.14M | -43.89M | -62.66M | -41.83M | -33.29M | -47.15M |
| Operating Income Ratio | 12.18% | 12.55% | 0.80% | -6.44% | -12.80% | -18.18% | -13.92% | -66.51% | -121.30% | -98.43% | -81.28% | -81.46% |
| Total Other Income/Expenses | -8.74M | -6.44M | -7.98M | -6.45M | -5.18M | -7.07M | -4.89M | -7.07M | -35.00K | 310.00K | 293.60K | -5.19M |
| Income Before Tax | 10.46M | 12.10M | -6.79M | -14.67M | -22.38M | -31.16M | -19.03M | -50.95M | -61.52M | -41.52M | -32.99M | -52.34M |
| Income Before Tax Ratio | 6.64% | 8.19% | -4.59% | -11.49% | -16.66% | -23.51% | -18.74% | -77.22% | -119.10% | -97.70% | -80.57% | -90.43% |
| Income Tax Expense | 10.00K | -45.00K | 37.00K | 55.00K | 40.00K | 192.00K | 334.00K | 333.00K | 83.00K | 26.00K | 27.30K | 693.70K |
| Net Income | 10.45M | 12.15M | -6.83M | -14.72M | -22.42M | -31.35M | -19.36M | -51.29M | -61.60M | -41.55M | -33.02M | -53.03M |
| Net Income Ratio | 6.63% | 8.22% | -4.61% | -11.53% | -16.69% | -23.65% | -19.07% | -77.73% | -119.26% | -97.76% | -80.63% | -91.63% |
| EPS | 0.86 | 1.02 | -0.58 | -1.43 | -2.08 | -2.89 | -1.79 | -5.07 | -6.09 | -4.17 | -3.40 | -5.53 |
| EPS Diluted | 0.86 | 1.02 | -0.58 | -1.43 | -2.08 | -2.89 | -1.79 | -5.07 | -6.09 | -4.17 | -3.40 | -5.53 |
| Weighted Avg Shares Out | 12.15M | 11.86M | 11.68M | 10.28M | 10.76M | 10.84M | 10.85M | 10.12M | 10.11M | 9.95M | 9.71M | 9.59M |
| Weighted Avg Shares Out (Dil) | 12.14M | 11.94M | 11.68M | 10.28M | 10.76M | 10.84M | 10.85M | 10.12M | 10.11M | 9.95M | 9.71M | 9.59M |
Are Medical Stocks Lagging Basilea Pharmaceutica (BPMUF) This Year?
Best Momentum Stock to Buy for August 28th
New Strong Buy Stocks for August 28th
Recent Price Trend in Basilea Pharmaceutica (BPMUF) is Your Friend, Here's Why
Is Basilea Pharmaceutica (BPMUF) Stock Outpacing Its Medical Peers This Year?
Basilea Pharmaceutica AG (BPMUF) Q2 2024 Earnings Call Transcript
Basilea Pharmaceutica (BPMUF) Is a Great Choice for 'Trend' Investors, Here's Why
US FDA approves Basilea Pharmaceutica's antibiotic
Basilea Pharmaceutica AG (BPMUF) Q4 2022 Earnings Call Transcript
Here's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep going
Source: https://incomestatements.info
Category: Stock Reports